Unknown PHASE3 INTERVENTIONAL 2-arm NCT03236636

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Comparison of Efficacy and Safety of Icaritin Versus Cinobufotalin in First-line Treatment of Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Double-blind, Double-dummy Phase III Clinical Trial

Sponsor: Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Conditions Advanced HBV-Related Hepatocellular Carcinoma (HCC)

Interventions HUACHANSU PIAN Icaritin

Updated 14 times since 2017 Last updated: Jan 25, 2021 Started: Sep 8, 2017 Primary completion: Dec 30, 2022 Completion: Dec 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03236636, this PHASE3 trial focuses on Advanced HBV-Related Hepatocellular Carcinoma (HCC) and remains ongoing. Sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University, it has been updated 14 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

14 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE3
Jul 2023 — Oct 2023 [monthly]

Unknown Status PHASE3
Feb 2023 — Jul 2023 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status

▶ Show 9 earlier versions

Dec 2022 — Feb 2023 [monthly]

Recruiting PHASE3
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE3
Oct 2021 — Nov 2022 [monthly]

Recruiting PHASE3
Feb 2021 — Oct 2021 [monthly]

Recruiting PHASE3

Status: Unknown Status → Recruiting
Jan 2021 — Feb 2021 [monthly]

Unknown Status PHASE3
Sep 2019 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status
Feb 2019 — Sep 2019 [monthly]

Not Yet Recruiting PHASE3
Jun 2018 — Feb 2019 [monthly]

Not Yet Recruiting PHASE3
Sep 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Anhui Provincial Hospital
Beijing Hospital
Beijing Shenogen Biomedical Co., Ltd
Chifeng Municipal Hospital
Chinese Academy of Medical Sciences
Chongqing Traditional Chinese Medicine Hospital
First People's Hospital of Foshan
Fudan University
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Guilin Medical University, China
Haikou People's Hospital
Hebei Medical University Fourth Hospital
Jinan Central Hospital
Linyi Tumour Hospital
NanJing PLA 81 Hospital
Nanfang Hospital, Southern Medical University
Peking University Cancer Hospital & Institute
The Affiliated Hospital of Hangzhou Normal University
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
The First Affiliated Hospital of Anhui Medical University
The First Affiliated Hospital of Zhengzhou University
The First Affiliated Hospital with Nanjing Medical University
The First Hospital of Jilin University
The Sixth People's Hospital of Shenyang
The Third Xiangya Hospital of Central South University
West China Hospital
Yunnan Provincial Hospital of Traditional Chinese Medicine

Data source: Beijing Shenogen Biomedical Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chifeng, China , Chongqing, China , Foshan, China , Guangzhou, China , Guilin, China , Haikou, China and 12 more locations